Steroid Tapering Strategy When Initiating Tofacitinib in Steroid-Refractory Severe UC
Continue IV hydrocortisone 100 mg TDS concurrently with tofacitinib 10 mg BD for the first 7 days, then rapidly taper and discontinue steroids over the following 7-14 days if clinical response is evident.
Rationale for Concurrent Therapy
The most recent evidence from the 2025 British Society of Gastroenterology guidelines 1 and emerging trial data 1 demonstrates that tofacitinib can be administered alongside intravenous corticosteroids in acute severe UC (ASUC). In a recent pilot RCT of 104 ASUC patients, tofacitinib 10 mg three times daily was given while continuing IV corticosteroids for 7 days, achieving 83% response rate versus 58.8% with placebo 1. This establishes that concurrent use is both safe and potentially synergistic in the acute phase.
Specific Tapering Protocol
Days 1-7 of Tofacitinib:
- Continue IV hydrocortisone 100 mg TDS unchanged
- Start tofacitinib 10 mg BD orally
- Monitor clinical response daily (stool frequency, rectal bleeding, vital signs)
Day 7 Assessment:
If clinical response achieved (≥3-point reduction in partial Mayo score with rectal bleeding ≤1):
- Switch from IV hydrocortisone to oral prednisolone 40 mg once daily
- Continue tofacitinib 10 mg BD
If inadequate response (still 8-9 bloody stools):
- Consider extending tofacitinib induction to 10 mg three times daily for additional 3-7 days while maintaining IV steroids 1
- Reassess for colectomy if no improvement by day 10-14
Days 8-21 (If Response Achieved):
- Rapid taper oral prednisolone: reduce by 10 mg every 3-4 days
- Day 8-10: 40 mg daily
- Day 11-14: 30 mg daily
- Day 15-17: 20 mg daily
- Day 18-21: 10 mg daily
- Day 22+: Discontinue steroids
- Continue tofacitinib 10 mg BD throughout
Critical Safety Considerations
Thrombosis Risk
This patient faces compounded thrombotic risk from both severe UC and tofacitinib. The BSG guidelines explicitly warn that ASUC itself is a thrombosis risk factor, and tofacitinib carries FDA black box warnings for venous thromboembolism 1. One patient in the recent RCT developed dural venous sinus thrombosis on tofacitinib 1.
Mandatory prophylaxis:
- Ensure therapeutic VTE prophylaxis (enoxaparin 40 mg SC daily minimum, consider higher dose given dual risk)
- Continue prophylaxis until ambulatory and disease controlled
- Maintain high index of suspicion for thrombotic events
Infection Monitoring
High-dose steroids plus tofacitinib increases infection risk. The 2025 BSG guidelines note no significant difference in infection rates comparing prednisolone >20 mg versus ≤20 mg 1, but prolonged dual immunosuppression should be minimized.
Screen for:
- CMV reactivation (if not already done) - high colonic CMV DNA (>50,000 copies/mL) predicts tofacitinib failure 2
- Herpes zoster risk (most common tofacitinib adverse event) 3, 4
- Tuberculosis reactivation 4
Duration of High-Dose Tofacitinib
The FDA label 5 and AGA guidelines 6 specify tofacitinib 10 mg BD for at least 8 weeks for induction, with evaluation for transition to maintenance dosing. However, your patient's plan of 8 weeks at 10 mg BD followed by 5 mg BD is appropriate.
Important caveat: Approximately 29% of patients de-escalated from 10 mg to 5 mg BD require dose re-escalation, with only 63% recapturing response 6. Given this patient's severe presentation (steroid-refractory with 8-9 stools/day on day 7), consider maintaining 10 mg BD for the full 8 weeks before attempting de-escalation, and monitor closely for relapse.
Why Not Abrupt Steroid Cessation?
Abrupt discontinuation of IV hydrocortisone after 7 days of 300 mg/day total dose risks:
- Adrenal insufficiency (though less likely with only 7 days exposure)
- Disease flare during the tofacitinib "ramp-up" period
The concurrent approach allows tofacitinib to establish therapeutic effect while maintaining disease control, then rapidly withdrawing steroids once response is confirmed.
Monitoring Response
Recent data shows 73% of steroid-refractory ASUC patients respond to tofacitinib within 7 days, and 90% within 10 days 7. If your patient shows no improvement by day 10 of tofacitinib, strongly consider colectomy rather than prolonging medical therapy, as outcomes worsen with delayed surgery.
The need for extended induction cycles beyond 8 weeks predicts higher colectomy risk 8, so early identification of non-responders is critical for morbidity reduction.